Extended Data Fig. 4: Disrupting the heightened liver alanine catabolism improves skeletal muscle size and function in mouse models of type 2 diabetes. Related to Fig. 4.
From: Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes
a, Body mass of lean C57Bl/6J (Bl6) and age-matched obese/diabetic BKS-db/db mice with hepatocyte selective AAV-miR mediated silencing of glutamic-pyruvic transaminase (Gpt) isoforms. NC: negative control. miR: micro-RNA. Data are mean ± SEM, N = 4/group. Effect of miR vs. NC miR: * P < 0.05, ** P < 0.01, *** P < 0.001. Effect of genotype: # P < 0.05, ## P < 0.01, ### P < 0.001. b, Lean body mass as determined by ECHO-MRI of mice as in A. c, Fat body mass as determined by ECHO-MRI of mice as in A. d, Body mass of mice on an obesogenic high-fat diet with (HFD-STZ) or without (HFD) streptozocin (STZ) pre-treatment to exacerbate the progression of frank diabetes; with hepatocyte selective AAV-miR mediated silencing of glutamic-pyruvic transaminase (Gpt) isoforms. NC: negative control. Data are mean ± SEM, N = 6/group. Effect of miR vs. NC miR: * P < 0.05, ** P < 0.01, *** P < 0.001. Effect of STZ: # P < 0.05, ## P < 0.01, ### P < 0.001. e, Lean body mass as determined by ECHO-MRI of mice as in D. f, Fat body mass as determined by ECHO-MRI of mice as in D. Statistical tests: A, B, C, D, E, F: 2-way ANOVA with Holm-Sidak posthoc hoc tests.
